Study to Nivolumab Following Preoperative Chemoradiotherapy

Cancer of Rectum Clinical Trial

Official title:

A Phase 1b/2 Multicenter Study to Investigate the Safety, Efficacy and Proof of Concept (POC) of Nivolumab Monotherapy as a Sequential Therapy Following Preoperative Chemoradiotherapy Patients With Locally Advanced Resectable Rectal Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02948348
• Other study ID #: EPOC1504
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 2016
• Est. completion date: August 2022

Study information

• Verified date: September 2021
• Source: National Cancer Center Hospital East
• Contact: Hideaki Bando, Dr
• Phone: +81-52-762-6111
• Email: voltage_core[@]east.ncc.go.jp
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase Ib/II, open-label, single-arm, multicenter study to investigate the safety, efficacy, and proof of concept (POC) of monotherapy with nivolumab, an anti-PD-1 antibody drug, as a sequential therapy following chemoradiotherapy (CRT) with capecitabine and subsequent surgical therapy in patients with locally advanced resectable rectal cancer.

Description:

[Phase Ib]

After preoperative CRT, to sequentially administer nivolumab in combination for patients with locally advanced resectable rectal cancer. To evaluate the safety of nivolumab in sequential combination therapy, the onset of dose-limiting toxicity (DLT) and the safety of subsequent surgical therapy, and to decide on a recommended dose (RD) for the phase II part.

[Phase II] PhaseⅡ is composed of 4 cohorts.

Cohort A: First-onset rectal cancer cohort (42 cases) To evaluate the efficacy and safety of nivolumab (at the RD determined in Phase Ib) in sequential combination with surgery, administered following preoperative CRT.

And to search for biomarkers related to therapeutic effects in first-onset cases. Evaluate the safety of surgical treatment.

Cohort B: Rectal cancer with localized recurrence cohort (10 cases) To conduct an exploratory evaluation of the efficacy and safety of nivolumab (at the RD determined in Phase Ib) in sequential combination with surgery, administered after preoperative CRT.

Search for biomarkers related to therapeutic effects in localized recurrence cases. Conduct an exploratory evaluation on the safety of surgical treatment.

Cohort C: Rectal cancer with resectable lung/liver metastasis cohort (10 cases) To conduct an exploratory evaluation of the efficacy and safety of nivolumab (at the RD determined in Phase Ib) in sequential combination with surgery, administered after preoperative CRT.

Search for biomarkers related to therapeutic effects in resectable lung/liver metastasis cases. Conduct an exploratory evaluation on the safety of surgical treatment.

Cohort D: First-onset rectal cancer using ipilimumab-nivolumab combination cohort (25 cases) To conduct an exploratory evaluation of the efficacy and safety of nivolumab (240 mg/body at two-week intervals) and ipilimumab (1 mg/kg at six-week intervals) after preoperative CRT, and search for biomarkers related to therapeutic effects in first-onset cases. Conduct an exploratory evaluation on the safety of surgical treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: August 2022
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 80 Years

Eligibility

Inclusion criteria:

(A. Phase Ib and Cohorts A and D only)

A1. Rectal cancer patients who have not undergone treatment for pre-CRT tumors situated 12 cm or less from the lower edge of the AV.

A2. The primary rectal lesion is histopathologically diagnosed as adenocarcinoma.

A3. Pre-CRT clinical stage is clinical T3-4 N-any M0.

A4. Macroscopic radical resection is deemed possible on pre-CRT image diagnosis.

A5. Aged between 20 and 80 years at the time of enrollment.

(B. Cohort B only)

B1. Clinically diagnosed with local recurrence after rectal surgery.

B2. The main site of recurrence is limited to the pelvis by pre-CRT imaging diagnosis.

B3. Macroscopic radical resection is deemed possible on pre-CRT imaging diagnosis.

B4. Aged between 20 and 75 years at the time of enrollment.

(C. Cohort C only)

C1. Rectal cancer patients who have not undergone pretreatment for a pre-CRT tumor which is 12 cm or less from the lower AV.

C2. The primary rectal lesion is histopathologically diagnosed as adenocarcinoma.

C3. The pre-CRT clinical stage is clinical T3-4 N-any M1a (liver) M1a (lungs).

C4. Macroscopic curative resection of the primary rectal lesion is deemed possible on pre-CRT imaging diagnosis.

C5. A metastatic liver tumor or a metastatic lung tumor has been diagnosed as clinically resectable prior to CRT and during clinical trial enrollment.

(D. Common to all cohorts in Phase Ib and Phase II)

D1. Patients who have provided consent through a consent form.

D2. Patients whose Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) is 0 or 1 at the time of enrollment.

D3. CRT was administered:

D4. Patients whose CRT adverse events have recovered to Grade 1 or lower based on CTCAE ver.4.0. within 14 days after the end of CRT, and are expected to be able to take nivolumab (patient is still eligible even if adverse events are not restored to Grade 1, provided that the blood cell count satisfies the eligibility criteria specified in point D8).

D5. Patients with no remote metastases as confirmed by imaging at the end of CRT (testing is allowed from 14 days before the end of CRT to the trial enrollment date).

D6. For women who may become pregnant (including patients who are not menstruating due to chemically-induced menopause among other medical reasons), patients who agree to use contraception for at least 23 weeks after the last administration of the investigational drug, starting from the day they provide consent (30 days (ovulation cycle) plus five times the elimination half-life of the investigational drug).

D7. For men, patients who agree to use contraception for at least 31 weeks after the last administration of the investigational drug, starting from the day they provide consent (90 days (spermatogenesis cycle) plus five times the elimination half-life of the investigational drug).

D8. Patients who have the sufficient organ function at the time of enrollment.

Exclusion criteria

1. Patients diagnosed with active double cancer (synchronous double cancer and double cancer with disease-free period within five years from enrollment).

However, lesions equivalent to intraepithelial or mucosal carcinoma deemed cured by localized treatment are not classified as active double cancer.

2. Patients with a history of pelvic irradiation prior to this rectal cancer treatment.

3. Patients who have not given consent through the informed consent form.

4. Patients deemed by the investigator to be ineligible for the trial.

Related Conditions & MeSH terms

• Cancer of Rectum
• Rectal Neoplasms

Intervention

Drug:
• Nivolumab
Capecitabine:Dose of 1650mg/m2,14days, Radiation:45Gy/25 fractions, Nivolumab :240mg on day1 of each cycle, Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
• Ipilimumab
For only Cohort D,1 mg/kg at six-week intervals

Locations

Country	Name	City	State
Japan	National Cancer Center Hospital East	Kashiwa	Chiba
Japan	Osaka National Hospital	Osaka
Japan	Hokkaido University	Sapporo	Hokkaido

Sponsors (2)

Lead Sponsor	Collaborator
Takayuki Yoshino	Ono Pharmaceutical Co. Ltd

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological complete response	Pathological complete response will be evaluated with American Joint Committee on Cancer (AJCC) Cancer Staging	1 year
Secondary	Objective response rate	Evaluation Criteria In Solid Tumors (RECIST)	1 year
Secondary	Recurrence pattern (local or distant)		1 year
Secondary	Disease-free survival (DFS)	Evaluation Criteria In Solid Tumors (RECIST)	5years
Secondary	Overall survival (OS)	Evaluation Criteria In Solid Tumors (RECIST)	5years
Secondary	Incidence of adverse events (AEs)	Safety will be evaluated with CTCAE v4.0	1 year
Secondary	Rate of completing the protocol therapy		1 year
Secondary	Rate of radical resection		1 year
Secondary	Safety evaluation	Safety will be evaluated with CTCAE v4.0	5years
Secondary	macroscopic evaluation of (rectal cancer) resected specimen		1 year